Anebulo Pharmaceuticals (NASDAQ:ANEB) Posts Quarterly Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) posted its quarterly earnings results on Thursday. The company reported ($0.05) EPS for the quarter, FiscalAI reports.

Anebulo Pharmaceuticals Stock Up 0.0%

Shares of NASDAQ:ANEB traded up $0.00 during midday trading on Thursday, hitting $0.47. 29,025 shares of the stock traded hands, compared to its average volume of 84,059. The business’s 50 day moving average is $1.31 and its two-hundred day moving average is $2.08. The stock has a market capitalization of $19.51 million, a PE ratio of -2.06 and a beta of -0.81. Anebulo Pharmaceuticals has a one year low of $0.44 and a one year high of $3.42.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals at the end of the most recent reporting period. 28.40% of the stock is owned by hedge funds and other institutional investors.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.